Cayuga Biotech is a startup company developing a commercially viable nanotherapeutic drug to treat both internal and external hemorrhage. The company envisions their product as a universal hemostat able to generate clots in all bleeding cases – compressible, non-compressible and internal injuries while minimizing the risk of side effects. SNNLive spoke with Damien Kudela, Founder of Cayuga Biotech at First Look LA 2014 presented by LAVA in Los Angeles, CA.
“Cayuga Biotech is a biotech startup that’s developing new clotting drugs. The big problem in hemorrhage right now is that if you’re in a car accident or if you’re a soldier the bomb goes off, you’re actually bleeding internally and you don’t know it and so what happens is that people eventually bleed to death before they can reach the hospital” begins Mr. Kedula.
Mr. Kudela explains, “What we’ve developed is a nanoparticle clotting agent that can be injected into the body, that glues itself to the clot and releases a drug that accelerates the body’s natural clotting process. So rather than forcing the body to clot, we’re really working with the body to increase efficacy and safety.” For more information, check out their website at www.cayugabiotech.com.
© 2017 Stock News Now
Supported by Superior Web Solutions